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Abstract
OBJECTIVE—Infections due to fluoroquinolone-resistant Escherichia coli (FQREC) are 
associated with significant morbidity and mortality. Fluoroquinolone resistance likely arises at the 
level of gastrointestinal colonization. The objective of this study was to identify risk factors for the 
development of FQREC gastrointestinal tract colonization in hospitalized patients, including the 
impact of antibiotics prescribed during hospitalization.
DESIGN—A prospective cohort study was conducted from 2002 to 2004 within a university 
health system.
METHODS—Hospitalized patients initially colonized with fluoroquinolone-susceptible E. coli 
were followed up with serial fecal sampling for new FQREC colonization or until hospital 
discharge or death. A Cox proportional hazards regression model was developed to identify risk 
factors for new FQREC colonization, with antibiotic exposure modeled as time-varying 
covariates.
RESULTS—Of 395 subjects, 73 (18.5%) became newly colonized with FQREC. Length of stay 
before sampling (hazard ratio [HR], 1.02 [95% confidence interval (CI), 1.1–1.03]; P = .003) and 
malignancy (HR, 0.37 [95% CI, 0.21–0.67]; P = .001) were significantly associated with the 
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development of FQREC colonization. In addition, receipt of a first-generation cephalosporin (HR, 
1.19 [95% CI, 1.10–1.29]; P < .001) or cefepime (HR, 1.05 [95% CI, 1.00–1.10]; P = .048) during 
hospitalization increased the risk of new FQREC colonization.
CONCLUSIONS—The acquisition of FQREC in the hospital setting is complex, and 
antimicrobial stewardship programs should take into account patterns of antibiotic use in 
implementing strategies to reduce the development of new FQREC colonization. Future studies 
are needed to identify risk factors for infection in hospitalized patients newly colonized with 
FQREC.
Since the introduction of ciprofloxacin in 1987, fluoroquinolones have rapidly become one 
of the most commonly prescribed classes of antibiotics.1 However, along with increases in 
fluoroquinolone (FQ) use, the prevalence of FQ-resistant organisms, particularly 
Escherichia coli, has significantly increased in both the healthcare and community setting.2 
Infections due to FQ-resistant E. coli (FQREC) have been associated with poor clinical 
outcomes, including greater mortality,3,4 and represent a major public health threat.
The emergence of FQ resistance in E. coli occurs as a multistep process, with increasing 
numbers of target gene mutations leading to progressively higher FQ minimum inhibitory 
concentrations (MICs).5–7 Studies have demonstrated that gastrointestinal tract colonization 
with FQREC may develop in response to antibiotic exposure,8,9 such that E. coli isolates 
causing clinical infections are most often derived from colonizing organisms. Despite this, 
the majority of studies evaluating risk factors for acquisition of FQREC have focused on 
clinical isolates causing infection.10–19 A smaller number of studies9,20–24 have evaluated 
risk factors for gastrointestinal tract colonization with FQREC in hospitalized patients. 
However, only a few of these studies9,22,24 have focused on risk factors for the acquisition 
of FQREC in patients initially colonized with FQ-susceptible E. coli (FQSEC), despite the 
fact that risk factors for baseline FQREC colonization near the time of admission are likely 
to differ from those for nosocomial acquisition. These studies were limited by small sample 
sizes,9,22,24 lack of multivariable analysis,24 and evaluation of acquisition of any FQ-
resistant gram-negative organism,9,22 with Pseudomonas aeruginosa predominating among 
the colonizing FQ-resistant isolates. Furthermore, although exposure to antibiotics is one of 
the most readily modifiable risk factors for the acquisition of FQREC in the hospital setting, 
earlier studies have focused on the dichotomous administration of antibiotics9,20,21 or 
formulary changes22 rather than the more complex patterns of use that occur in the hospital 
setting.
Evaluating risk factors for the acquisition of FQREC in patients initially colonized with 
FQSEC is critical for informing potential interventions to limit the emergence of FQREC in 
the hospital setting. Furthermore, elucidation of the selection pressure exerted by the time-
varying use of antibiotics will be critical in the development of effective antimicrobial 
stewardship strategies. Therefore, we conducted this study to identify risk factors for the 
development of FQREC gastrointestinal tract colonization in hospitalized patients, including 
the impact of patterns of antibiotic prescription during hospitalization.
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Study Design and Setting
A prospective cohort study was conducted at 2 hospitals in the University of Pennsylvania 
Health System (UPHS) in Philadelphia: hospital 1, a 725-bed academic tertiary care medical 
center, and hospital 2, a 344-bed urban community hospital. Three hospital-wide annual 
fecal surveillance surveys were conducted at hospital 1 and hospital 2, as previously 
described,20,25 during the years 2002, 2003, and 2004. For this study, target units were 
selected on the basis of high prevalence rates of FQREC as previously determined by the 
annual surveys (4 units at hospital 1 and 2 units at hospital 2).
Target units were surveyed over a 3-month period, with all patients admitted to the unit 
eligible for inclusion in our study cohort. On the first day of a unit survey, all patients 
hospitalized on the unit by 8:00 am were identified and approached for informed consent. 
For patients unable to provide informed consent, a legal decision maker (eg, family member) 
was approached for informed consent. Fecal samples were obtained from patients who 
provided informed consent and submitted to the Hospital of the University of Pennsylvania 
Clinical Microbiology Laboratory for processing. Study patients were followed up 
longitudinally and continued to have fecal samples submitted every 48–72 hours until the 
time of hospital discharge or death. New patients admitted to the unit during the survey 
period were also eligible to be enrolled in the study. At the end of the 3-month enrollment 
period, all patients currently undergoing surveillance continued to be followed up until the 
time of hospital discharge or death. However, no new patients were enrolled during the third 
month of the survey to allow for complete follow-up of all patients already enrolled. Each 
patient was included as a subject only once, with only the first episode of eligibility 
included. The study was approved by the institutional review board of the University of 
Pennsylvania.
Study Population
The source population for the present study consisted of all patients who were determined to 
be colonized with FQ-susceptible E. coli on the initial surveillance culture. These patients 
were subsequently followed up with serial fecal samples obtained every 48–72 hours as 
described until recovery of FQREC or discharge or death.
Microbiological Methods
Detection of E. coli with reduced FQ susceptibility from fecal samples was performed as 
previously described,20,25 with levofloxacin used as a marker for susceptibility to FQs. 
Isolates with MICs in the susceptible but elevated range (ie, reduced FQ susceptibility) may 
harbor mutations in FQ target genes and, given the multistep nature of development of FQ 
resistance, are critical in explaining the emergence of FQ resistance.5–7,26 Therefore, for the 
present study, FQ resistance was defined as a levofloxacin MIC greater than or equal to 0.25 
μg/mL.25
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Data were abstracted from the Pennsylvania Integrated Clinical and Administrative 
Research Database,27,28 which includes demographic, laboratory, pharmacy, and billing 
information. The following data were collected for all patients: demographic characteristics, 
surveillance year, hospital of admission, transfer from another institution or nursing home, 
admissions to UPHS in the 30 days before sampling, service location at the time of sampling 
(ie, medicine vs surgery), and hospital length of stay before the initial surveillance culture. 
Data on comorbid conditions were also ascertained at the time of the sampling, including 
diabetes mellitus, malignancy, renal insufficiency (creatinine level ≥2.0 mg/dL or receiving 
dialysis), hepatic dysfunction (eg, cirrhosis), human immunodeficiency virus infection, solid 
organ or hematopoietic stem cell transplant, neutropenia (absolute neutrophil count, <500 
neutrophils/mm3), significant cardiovascular disease (eg, severe congestive heart failure), 
significant respiratory disease (eg, severe chronic obstructive pulmonary disease and chronic 
bronchitis), and any surgical procedure performed in the 30 days before sampling. Data on 
the presence of a urinary catheter, central venous catheter, or diarrhea before the initial 
surveillance culture were collected for all patients. Furthermore, data on the receipt of 
corticosteroids or other immunosuppressive agents in the 30 days before fecal sampling 
were documented.
Assessment of Antibiotic Exposures
Data were obtained on all antibiotics administered from the initial surveillance culture to 
new FQREC colonization or discharge or death (ie, the time at risk). For the purposes of 
analysis, antibiotics were categorized by class or by specific agent, if only one agent of a 
given class was used, as follows: levofloxacin, cefepime, vancomycin, aminoglycosides (ie, 
gentamicin and tobramycin), piperacillin-tazobactam, nafcillin, other penicillins (ie, 
amoxicillin-clavulanate and ampicillin-sulbactam), first-generation cephalosporins (ie, 
cephalexin and cefazolin), trimethoprim-sulfamethoxazole, doxycycline, metronidazole, 
imipenem, and clindamycin. Antibiotics were subsequently assessed as time-varying 
covariates (exposed vs nonexposed on a given day).
Statistical Analysis
Standard methods of survival analysis were used to determine the association between 
potential risk factors and time to development of colonization with FQREC. Time zero for 
all patients was defined as the day of the initial surveillance culture. Bivariable analyses 
were performed to evaluate risk factors for development of new FQREC colonization during 
hospitalization using Kaplan-Meier product-limit survival curve estimates and the log rank 
statistic for the comparison of multiple survival curves. Multivariable analyses were 
subsequently performed using Cox proportional hazards regression analyses with antibiotic 
exposure modeled as time-varying covariates to account for different timing and durations 
of therapy. A stepwise selection procedure was used, with variables with P values less than .
20 on bivariable analyses considered as candidate variables and maintained in the final 
model if their inclusion was statistically significant on likelihood ratio testing.29 Hospital 
length of stay before the initial sample was retained a priori in the model regardless of its 
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significance on bivariable analyses given its clinical importance. A hazard ratio (HR) and 
95% confidence interval (CI) were calculated to evaluate the strength of any association.
For all calculations, a 2-tailed P value less than .05 was considered to be significant. All 




During the 3-year study period, a total of 522 (44.0%) of 1,186 patients who were 
approached for enrollment provided informed consent. There were no significant differences 
with regard to mean age, race and ethnicity, year of enrollment, and hospital of admission 
when comparing patients who did and did not enroll in the study. A total of 516 patients had 
initial fecal cultures positive for E. coli, of which 451 (87.4%) were FQ-susceptible 
(levofloxacin MIC, <0.25 μg/mL). Of these 451 patients who were colonized with FQSEC, 
395 underwent subsequent serial sampling during hospitalization (ie, had at least 1 sample 
following the initial surveillance culture) and represented the primary study cohort. The 
mean age (± standard deviation [SD]) of patients was 62 ± 15.6 years, and 216 (54.7%) were 
male. Of the 395 patients, 239 (60.5%) were white, 131 (33.2%) were Black, 4 (1.0%) were 
Asian, 2 (0.5%) were Hispanic, and the remainder were self-identified as “other.” A total of 
320 patients (81.0%) were hospitalized at hospital 1, whereas 75 (19.0%) were hospitalized 
at hospital 2. Finally, of the 395 patients, a total of 284 (71.9%) received at least 1 day of an 
antibiotic during the sampling period. The most commonly prescribed antibiotics after the 
initial surveillance culture were vancomycin (n = 92; 23.3%), cefepime (n = 86; 21.8%), 
metronidazole (n = 86; 21.8%), levofloxacin (n = 81; 20.5%), and a first-generation 
cephalosporin (n = 59; 14.9%).
Microbiological Results
Of the 395 patients initially colonized with FQSEC who underwent serial sampling, 73 
(18.5%) patients developed colonization with FQREC during hospitalization. Of these, 36 
patients had an isolate with high-level FQ resistance (levofloxacin MIC, ≥8 μg/mL), and 37 
patients had an isolate with low-level FQ resistance (levofloxacin MIC, ≥0.25 μg/mL but 
<8.0 μg/mL). The mechanisms of resistance of these isolates have been previously 
described.30 Finally, there was no evidence of clonal relatedness of the 73 unique FQREC 
isolates based on molecular typing by pulsed-field gel electrophoresis (PFGE).
Risk Factors for the Development of FQREC Colonization
A total of 73 patients (18.5%) had a subsequent culture positive for FQREC. The median 
time to the isolation of FQREC among these patients was 7 days (interquartile range [IQR], 
4–16). In bivariable analyses, several variables were noted to be significantly associated 
with acquisition of FQREC colonization (Table 1). For example, patients who developed 
FQREC colonization, compared with those who remained colonized with FQSEC, were 
more likely to have been hospitalized at hospital 2 (23.3% vs 18.0%; P < .001), been 
admitted from a nursing home (6.9% vs 5.0%; P = .02), and had a central venous catheter 
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present before sampling (23.3% vs 18.0%; P = .02). In addition, patients who developed 
new FQREC colonization, compared with those who remained colonized with FQSEC 
during the sampling period, had greater exposure to cefepime (median, 7 days [IQR, 5–10] 
vs 4.5 days [IQR, 2–8.5]) and a first-generation cephalosporin (median, 5 days [IQR, 2–8] 
vs 3 days [IQR, 2–5]).
On multivariable analysis using Cox proportional hazards regression (Table 2), risk factors 
for acquisition of FQREC included duration of hospitalization before the initial sample (HR, 
1.02 [95% CI, 1.01–1.03]; P = .003) and admission to hospital 2 (HR, 2.05 [95% CI, 1.12–
3.74]; P = .02). Malignancy was protective against the development of FQREC colonization 
(HR, 0.37 [95% CI, 0.21–0.67]; P = .001). Finally, after controlling for confounders, the 
receipt of cefepime (HR, 1.05 [95% CI, 1.00–1.11]; P = .048) or a first-generation 
cephalosporin (HR, 1.19 [95% CI, 1.10–1.29]; P < .001) during hospitalization was 
associated with an increased risk of acquisition of FQREC. The receipt of FQ was not 
significant in the final model (HR, 0.99 [95% CI, 0.94–1.06]; P = .86).
DISCUSSION
In this 3-year prospective cohort study, we found that a total of 73 patients (18.5%) became 
newly colonized with FQREC during hospitalization. Risk factors for the acquisition of 
FQREC in patients initially colonized with FQSEC included duration of hospitalization and 
admission to 1 of 2 study hospitals. Furthermore, the receipt of cefepime or a first-
generation cephalosporin during hospitalization, measured as time-varying exposures, 
increased the risk of FQREC acquisition.
Numerous studies evaluating risk factors for FQ resistance in E. coli clinical isolates have 
implicated previous FQ use,10–19 both as prophylaxis and as treatment. However, the 
emergence of FQ resistance in E. coli is likely to occur at the level of gastrointestinal tract 
colonization, and risk factors for FQREC, including antibiotic selection pressure, may differ 
depending on assessment of colonizing E. coli versus clinical isolates. Indeed, in our study 
and others,9,21,22,24 previous FQ use was not identified as a risk factor for FQREC 
colonization in hospitalized patients. In particular, it is possible that, rather than driving the 
emergence of FQREC through de novo mutations in existing colonizing FQSEC, antibiotic 
exposures during hospitalization may select for FQREC isolates that were present at low 
numbers in patients colonized with multiple strains. The results of our study are further 
strengthened by the large sample size, evaluation solely of E. coli versus multiple gram-
negative organisms (ie, for which different risk factors for resistance may exist), and 
evaluation of antibiotics received in the hospital setting as time-varying covariates versus 
dichotomous variables.
A novel finding of our study was that acquisition of FQREC colonization was associated 
with prescription of cefepime and first-generation cephalosporins after initial colonization 
with FQSEC. An earlier study22 evaluating the effect of a hospital-wide formulary change 
from ciprofloxacin to levofloxacin identified exposure to aminoglycosides and ceftazidime 
as risk factors for the development of colonization with FQ-resistant gram-negative 
organisms (eg, P. aeruginosa and E. coli). However, antibiotic exposures in this study were 
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evaluated as dichotomous variables (ie, exposure was evaluated as yes vs no). The use of 
different methods of describing previous antibiotic exposure (ie, dichotomous vs 
continuous) has been shown to substantially impact the identification of risk factors for 
antibiotic-resistant organisms,31 and we sought to more fully characterize the complex 
patterns of exposure that occur after hospital admission by modeling antibiotic use as time-
varying covariates.
The mechanism as to why the prescription of cephalosporins (no patients received 
ceftriaxone or ceftazidime in this study) was associated with isolation of FQREC is unclear, 
but it is possible that the use of antibiotics that are frequently active against the susceptible 
but not the resistant form of the organism (in particular, the first-generation cephalosporins) 
may have selected for emergence of colonizing FQREC isolates. Earlier studies have 
demonstrated high rates of co-resistance to other antibiotics in FQREC,25,32–34 particularly 
in isolates with efflux pump overexpression as the predominant mechanism of resistance. 
Indeed, in a study evaluating risk factors for efflux pump overexpression in FQREC,35 the 
receipt of a first-generation cephalosporin was identified as a significant risk factor on 
multivariable analysis. In a case-case-control study evaluating the association between FQ 
use and isolation of FQ-resistant E. coli and Klebsiella pneumoniae,36 previous exposure to 
any cephalosporin (eg, narrow spectrum or extended spectrum) was protective against 
isolation of FQ-susceptible organisms. Therefore, while the exact mechanisms leading to 
this association need to be further elucidated, consideration of this finding will be important 
in the implementation of antibiotic stewardship measures, particularly in institutions with 
high rates of cephalosporin use.
The results of our study also demonstrated a protective effect of malignancy on acquisition 
of FQREC, possibly due to the majority of oncology patients being hospitalized at hospital 1 
versus hospital 2. Along these lines, hospitalization at hospital 2 was associated with a 
significantly increased risk of FQREC acquisition on multivariable analysis. It is possible 
that this association may reflect differences in the local resistance profiles for the specific 
catchment areas of the 2 hospitals. Furthermore, although the results of PFGE testing did not 
demonstrate any clonal relatedness that would suggest an outbreak of a specific strain (ie, 
confined to a single hospital), it is possible that increased patient-to-patient or health-care-
worker-to-patient spread in a smaller hospital may have been a mediator of this association.
There are several potential limitations of this study. Selection bias is a potential concern, 
because only ~45% of eligible subjects were enrolled. However, participants and 
nonparticipants were similar in regard to demographic characteristics, year of enrollment, 
and hospital of admission. In addition, sampling variability may have limited the detection 
of colonizing FQREC isolates from a single patient, particularly those present in low 
numbers. Finally, this study was conducted in a single healthcare system, and these results 
may not be generalizable to other institutions with differing characteristics.
In conclusion, our study demonstrated a relatively high incidence of nearly 20% for new 
colonization with FQREC in the hospital setting. We found that the use of cefepime or a 
first-generation cephalosporin conferred an increased risk of colonization with FQREC in 
hospitalized patients initially colonized with FQSEC. The results of our study also highlight 
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the importance of assessing risk factors for the development of colonization and infection 
with FQREC independently. The development of FQ resistance in E. coli is complex, and 
future studies will need to focus on the evaluation of strategies to limit the spread of these 
increasingly prevalent organisms as well as risk factors for subsequent infection in patients 
with acquisition of FQREC in the hospital setting.
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TABLE 1
Characteristics Associated with the Development of Fluoroquinolone-Resistant Escherichia coli Colonization 
in Hospitalized Patients
Variable FQREC negative (n = 322) FQREC positive (n = 73) P
Mean age (±SD), years 61.3 ± 15.1 63.2 ± 17.6 .31
Female sex 142 (44.1) 37 (50.7) .26
Nonwhite race 124 (38.5) 32 (43.8) .05
Surgical service 72 (22.4) 12 (16.4) .02
LOS before the initial sample, days, median (IQR) 2 (1–5) 5 (1–12) <.001
Hospital 2 58 (18.0) 17 (23.3) <.001
Year of culture
 2002 (reference) 97 (30.1) 32 (43.8)
 2003 225 (69.9) 41 (56.2) .02
Admitted from nursing home 16 (5.0) 5 (6.9) .02
Transferred from another hospital 43 (13.4) 14 (19.2) .77
UPHS admission in previous 30 days 99 (30.8) 27 (37.0) .98
Urinary catheter 132 (41.0) 37 (50.7) .25
Mechanical ventilation 45 (14.0) 18 (24.7) .63
Central venous catheter 153 (47.5) 41 (56.2) .02
Diarrhea present 11 (3.4) 8 (11.0) .53
Diabetes mellitus 77 (23.9) 16 (21.9) .61
Neutropenia 9 (3.1) 0 (0.0) .13
Hepatic dysfunction 11 (3.4) 4 (5.5) .66
Severe cardiovascular disease 44 (13.7) 8 (11.0) .90
Severe respiratory disease 40 (12.4) 7 (9.6) .36
HIV infection 6 (1.9) 2 (2.7) .02
Malignancy 147 (45.4) 18 (24.7) <.001
Receipt of transplant 19 (6.1) 6 (8.7) .69
Renal insufficiency 46 (14.3) 13 (17.8) .59
Surgical procedure in previous 30 days 56 (17.4) 21 (28.8) .20
Receipt of corticosteroids in previous 30 days 43 (13.4) 10 (13.7) .78
NOTE. Data are no. (%) of patients, unless otherwise indicated. FQREC, fluoroquinolone-resistant E. coli; HIV, human immunodeficiency virus; 
IQR, interquartile range; LOS, length of stay; SD, standard deviation; UPHS, University of Pennsylvania Health System.
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TABLE 2
Multivariable Cox Proportional Hazards Regression Model of Risk Factors Associated with Fluoroquinolone-
Resistant Escherichia coli Colonization in Hospitalized Patients
Variable HR (95% CI) P
LOS before the initial sample 1.02 (1.01–1.03) .003
Admission to hospital 2 2.05 (1.12–3.74) .02
Central venous catheter 0.67 (0.40–1.13) .13
Malignancy 0.37 (0.21–0.67) .001
Receipt of cefepime
a 1.05 (1.00–1.10) .048
Receipt of a first-generation cephalosporin
a,b 1.19 (1.10–1.29) <.001
NOTE. CI, confidence interval; HR, hazard ratio; LOS, length of stay.
a
Modeled as a time-varying covariate.
b
Cefazolin and cephalexin.
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